Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Orally Administered PAX-1 in Brain Metastases from NSCLC
KCT0005636Phase 2Recruiting
- Sponsor
- Komipharm International Australia
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium arsenite in non-small cell lung cancer (NSCLC), sponsored by Komipharm International Australia. Started Oct 2020; status: recruiting.
02
Drugs
sodium arsenite
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0005636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005636.